Lent-On-Plus Lentiviral vectors for conditional expression in human stem cells

Conditional transgene expression in human stem cells has been difficult to achieve due to the low efficiency of existing delivery methods, the strong silencing of the transgenes and the toxicity of the regulators. Most of the existing technologies are based on stem cells clones expressing appropriat...

Full description

Saved in:
Bibliographic Details
Published inScientific reports Vol. 6; no. 1; p. 37289
Main Authors Benabdellah, Karim, Muñoz, Pilar, Cobo, Marién, Gutierrez-Guerrero, Alejandra, Sánchez-Hernández, Sabina, Garcia-Perez, Angélica, Anderson, Per, Carrillo-Gálvez, Ana Belén, Toscano, Miguel G, Martin, Francisco
Format Journal Article
LanguageEnglish
Published England Nature Publishing Group 17.11.2016
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Conditional transgene expression in human stem cells has been difficult to achieve due to the low efficiency of existing delivery methods, the strong silencing of the transgenes and the toxicity of the regulators. Most of the existing technologies are based on stem cells clones expressing appropriate levels of tTA or rtTA transactivators (based on the TetR-VP16 chimeras). In the present study, we aim the generation of Tet-On all-in-one lentiviral vectors (LVs) that tightly regulate transgene expression in human stem cells using the original TetR repressor. By using appropriate promoter combinations and shielding the LVs with the Is2 insulator, we have constructed the Lent-On-Plus Tet-On system that achieved efficient transgene regulation in human multipotent and pluripotent stem cells. The generation of inducible stem cell lines with the Lent-ON-Plus LVs did not require selection or cloning, and transgene regulation was maintained after long-term cultured and upon differentiation toward different lineages. To our knowledge, Lent-On-Plus is the first all-in-one vector system that tightly regulates transgene expression in bulk populations of human pluripotent stem cells and its progeny.
Bibliography:These authors contributed equally to this work.
These authors jointly supervised this work.
Present address: Amarna Therapeutics S.L., Marie Curie Building, C/Leonardo da Vinci 18a. Isla de la Cartuja, 41092 Seville, Spain.
Present address: University College London-Institute of Child Health, 30 Guilford Street. WC1N 1EH. London, United Kingdom.
Present address: Max-Delbrück-Center for Molecular Medicine, Berlin, Germany.
ISSN:2045-2322
2045-2322
DOI:10.1038/srep37289